Revenue: The sum of all revenue fields included for a company's operating activities.
BridgeBio Pharma, Inc. (BBIO) had Revenue of $221.90M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
|
Revenue |
$221.90M |
$-535.76M |
|
$3.88M |
|
$218.02M |
|
$814.88M |
|
$-592.97M |
|
$50.78M |
|
$-542.19M |
|
$-542.19M |
|
$-543.35M |
|
$-543.35M |
|
$-543.35M |
|
$-543.35M |
|
$-592.97M |
|
$-586.90M |
|
186.08M |
|
186.08M |
|
$-2.88 |
|
$-2.88 |
|
| Balance Sheet Financials | |
$720.69M |
|
$7.01M |
|
$198.65M |
|
$919.34M |
|
$154.40M |
|
$1.72B |
|
$2.22B |
|
$2.38B |
|
$-1.46B |
|
$-1.48B |
|
$-1.46B |
|
190.04M |
|
| Cash Flow Statement Financials | |
$-520.73M |
|
$60.78M |
|
$748.46M |
|
$394.73M |
|
$683.24M |
|
$288.51M |
|
$95.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.67 |
|
-- |
|
-- |
|
6.53 |
|
-1.18 |
|
98.25% |
|
-267.22% |
|
-267.22% |
|
-264.49% |
|
-244.34% |
|
-241.44% |
|
$-521.66M |
|
-- |
|
-- |
|
-- |
|
0.24 |
|
-- |
|
46.99 |
|
7.77 |
|
37.27% |
|
36.67% |
|
-59.10% |
|
-206.10% |
|
$-7.67 |
|
$-2.80 |
|
$-2.80 |
|